Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. The company's Alpha-DaRT technology is in clinical trials for various forms comprising skin, oral, pancreatic, prostate, lung, liver, and breast cancers; preclinical or pending clinical studies for brain and other cancers; and preclinical studies for hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others. Alpha Tau Medical Ltd. was incorporated in 2015 and is headquartered in Jerusalem, Israel. more
Time Frame | DRTS | Sector | S&P500 |
---|---|---|---|
1-Week Return | 3.19% | 0.49% | -0.42% |
1-Month Return | 6.6% | -3.1% | -2.2% |
3-Month Return | 43.56% | -8.59% | 2.38% |
6-Month Return | 48.17% | -4.57% | 5.1% |
1-Year Return | -2.12% | -0.94% | 23.79% |
3-Year Return | -67.34% | 2.88% | 26.66% |
5-Year Return | -68.02% | 35.84% | 81.16% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Cost of Revenue | - | 86.00K | 776.00K | 979.00K | 1.07M | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":8.01,"profit":true},{"date":"2021-12-31","value":72.25,"profit":true},{"date":"2022-12-31","value":91.15,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Profit | - | (86.00K) | (776.00K) | (979.00K) | (1.07M) | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-8600000,"profit":false},{"date":"2021-12-31","value":-77600000,"profit":false},{"date":"2022-12-31","value":-97900000,"profit":false},{"date":"2023-12-31","value":-107400000,"profit":false}] |
Gross Margin | - | (Infinity%) | (Infinity%) | (Infinity%) | (Infinity%) | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":null,"profit":false},{"date":"2021-12-31","value":null,"profit":false},{"date":"2022-12-31","value":null,"profit":false},{"date":"2023-12-31","value":null,"profit":false}] |
Operating Expenses | 8.01M | 9.24M | 13.79M | 32.14M | (35.68M) | [{"date":"2019-12-31","value":24.93,"profit":true},{"date":"2020-12-31","value":28.77,"profit":true},{"date":"2021-12-31","value":42.91,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-111.03,"profit":false}] |
Operating Income | (8.01M) | (9.24M) | (13.79M) | (32.14M) | 35.68M | [{"date":"2019-12-31","value":-22.45,"profit":false},{"date":"2020-12-31","value":-25.91,"profit":false},{"date":"2021-12-31","value":-38.65,"profit":false},{"date":"2022-12-31","value":-90.07,"profit":false},{"date":"2023-12-31","value":100,"profit":true}] |
Total Non-Operating Income/Expense | 457.00K | 1.14M | (13.28M) | 163.00K | (60.10M) | [{"date":"2019-12-31","value":40.02,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-1162.78,"profit":false},{"date":"2022-12-31","value":14.27,"profit":true},{"date":"2023-12-31","value":-5263.13,"profit":false}] |
Pre-Tax Income | (8.32M) | (8.72M) | (27.26M) | (33.74M) | (29.14M) | [{"date":"2019-12-31","value":-831800000,"profit":false},{"date":"2020-12-31","value":-872400000,"profit":false},{"date":"2021-12-31","value":-2726400000,"profit":false},{"date":"2022-12-31","value":-3374200000,"profit":false},{"date":"2023-12-31","value":-2914100000,"profit":false}] |
Income Taxes | 146.00K | 158.00K | 7.00K | 20.00K | 16.00K | [{"date":"2019-12-31","value":92.41,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":4.43,"profit":true},{"date":"2022-12-31","value":12.66,"profit":true},{"date":"2023-12-31","value":10.13,"profit":true}] |
Income After Taxes | (8.46M) | (8.88M) | (27.27M) | (33.76M) | (29.16M) | [{"date":"2019-12-31","value":-846400000,"profit":false},{"date":"2020-12-31","value":-888200000,"profit":false},{"date":"2021-12-31","value":-2727100000,"profit":false},{"date":"2022-12-31","value":-3376200000,"profit":false},{"date":"2023-12-31","value":-2915700000,"profit":false}] |
Income From Continuous Operations | (8.46M) | (8.88M) | (27.27M) | (33.76M) | (29.16M) | [{"date":"2019-12-31","value":-846400000,"profit":false},{"date":"2020-12-31","value":-888200000,"profit":false},{"date":"2021-12-31","value":-2727100000,"profit":false},{"date":"2022-12-31","value":-3376200000,"profit":false},{"date":"2023-12-31","value":-2915700000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (8.46M) | (8.88M) | (27.27M) | (33.76M) | (29.16M) | [{"date":"2019-12-31","value":-846400000,"profit":false},{"date":"2020-12-31","value":-888200000,"profit":false},{"date":"2021-12-31","value":-2727100000,"profit":false},{"date":"2022-12-31","value":-3376200000,"profit":false},{"date":"2023-12-31","value":-2915700000,"profit":false}] |
EPS (Diluted) | - | - | (0.12) | (0.66) | (0.42) | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":-12,"profit":false},{"date":"2022-12-31","value":-66,"profit":false},{"date":"2023-12-31","value":-42,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
DRTS | |
---|---|
Cash Ratio | 10.27 |
Current Ratio | 10.99 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
DRTS | |
---|---|
ROA (LTM) | -21.92% |
ROE (LTM) | -33.17% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
DRTS | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.24 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.76 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
DRTS | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 0.00 |
P/B | 3.26 |
EV/R | 0.00 |
EV/Ebitda | NM |
Alpha Tau Medical Ltd (DRTS) share price today is $3.23
Yes, Indians can buy shares of Alpha Tau Medical Ltd (DRTS) on Vested. To buy Alpha Tau Medical Ltd from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in DRTS stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Alpha Tau Medical Ltd (DRTS) via the Vested app. You can start investing in Alpha Tau Medical Ltd (DRTS) with a minimum investment of $1.
You can invest in shares of Alpha Tau Medical Ltd (DRTS) via Vested in three simple steps:
The 52-week high price of Alpha Tau Medical Ltd (DRTS) is $3.89. The 52-week low price of Alpha Tau Medical Ltd (DRTS) is $1.75.
The price-to-earnings (P/E) ratio of Alpha Tau Medical Ltd (DRTS) is
The price-to-book (P/B) ratio of Alpha Tau Medical Ltd (DRTS) is 3.26
The dividend yield of Alpha Tau Medical Ltd (DRTS) is 0.00%
The market capitalization of Alpha Tau Medical Ltd (DRTS) is $226.43M
The stock symbol (or ticker) of Alpha Tau Medical Ltd is DRTS